PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
16 02 2021
Historique:
entrez: 3 2 2021
pubmed: 4 2 2021
medline: 23 7 2021
Statut: ppublish

Résumé

Unlike other cell types, developing B cells undergo multiple rounds of somatic recombination and hypermutation to evolve high-affinity antibodies. Reflecting the high frequency of DNA double-strand breaks, adaptive immune protection by B cells comes with an increased risk of malignant transformation. B lymphoid transcription factors (e.g., IKZF1 and PAX5) serve as metabolic gatekeepers by limiting glucose to levels insufficient to fuel transformation. We here identified aberrant expression of the lactonase PON2 in B cell acute lymphoblastic leukemia (B-ALL) as a mechanism to bypass metabolic gatekeeper functions. Compared to normal pre-B cells, PON2 expression was elevated in patient-derived B-ALL samples and correlated with poor clinical outcomes in pediatric and adult cohorts. Genetic deletion of

Identifiants

pubmed: 33531346
pii: 2016553118
doi: 10.1073/pnas.2016553118
pmc: PMC7896313
pii:
doi:

Substances chimiques

Glucose Transporter Type 1 0
Membrane Proteins 0
SLC2A1 protein, human 0
STOM protein, human 0
Adenosine Triphosphate 8L70Q75FXE
Aryldialkylphosphatase EC 3.1.8.1
PON2 protein, human EC 3.1.8.1
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P01 CA233412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157644
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213138
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197628
Pays : United States
Organisme : Howard Hughes Medical Institute
ID : 55108547
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Nat Genet. 2014 Feb;46(2):116-25
pubmed: 24413735
Nat Med. 2017 Jan;23(1):79-90
pubmed: 27941793
Cell. 2012 Aug 31;150(5):1068-81
pubmed: 22939629
Blood. 2010 Feb 18;115(7):1394-405
pubmed: 19880498
Blood. 2014 Dec 18;124(26):3932-8
pubmed: 25349177
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
J Clin Invest. 1975 Dec;56(6):1499-1508
pubmed: 1202081
N Engl J Med. 2006 Jan 12;354(2):166-78
pubmed: 16407512
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Biol Chem. 2010 Aug 6;285(32):24398-403
pubmed: 20530481
J Biol Chem. 1996 Dec 6;271(49):31372-8
pubmed: 8940145
Mol Biol Cell. 2007 Apr;18(4):1437-46
pubmed: 17301289
Obesity (Silver Spring). 2011 Sep;19(9):1908-11
pubmed: 21720424
Nat Immunol. 2015 Jul;16(7):766-774
pubmed: 25985233
Cancer. 2004 Mar 15;100(6):1179-85
pubmed: 15022284
Blood. 2003 Oct 15;102(8):2951-9
pubmed: 12730115
Leukemia. 1994 Jul;8(7):1224-9
pubmed: 8035616
Cell. 2018 Apr 5;173(2):470-484.e18
pubmed: 29551267
Am J Physiol Cell Physiol. 2001 May;280(5):C1277-83
pubmed: 11287341
Cancer Discov. 2014 Apr;4(4):423-33
pubmed: 24469106
FASEB J. 2014 Apr;28(4):1769-79
pubmed: 24421402
J Biol Chem. 2013 Aug 16;288(33):23914-27
pubmed: 23788644
Cancer Res. 2018 May 15;78(10):2669-2679
pubmed: 29490943
J Biol Chem. 2015 Mar 13;290(11):7247-58
pubmed: 25627690
Immunol Rev. 2015 Jan;263(1):192-209
pubmed: 25510278
Cell Death Dis. 2013 Oct 03;4:e820
pubmed: 24091663
Cell Death Dis. 2011 Jan 13;2:e112
pubmed: 21368884
J Biol Chem. 2006 Oct 6;281(40):29491-500
pubmed: 16891303
Nat Rev Immunol. 2019 May;19(5):337-348
pubmed: 30890785
J Clin Oncol. 2017 Feb;35(4):394-401
pubmed: 27870571
J Clin Oncol. 2007 May 20;25(15):2063-9
pubmed: 17513811
Infect Immun. 2015 Sep;83(9):3369-80
pubmed: 26056385
Nature. 2017 Feb 23;542(7642):479-483
pubmed: 28192788
Nature. 2020 Dec;588(7838):491-497
pubmed: 33149299
Cell Death Dis. 2014 Oct 16;5:e1470
pubmed: 25321477
Cell. 2008 Mar 21;132(6):1039-48
pubmed: 18358815
Blood. 2010 Dec 2;116(23):4874-84
pubmed: 20699438
Exp Hematol. 2017 Sep;53:1-6
pubmed: 28655536
Antioxid Redox Signal. 2011 Feb 1;14(3):341-51
pubmed: 20578959
Mol Cell. 2017 Aug 17;67(4):685-701.e6
pubmed: 28803777

Auteurs

Lili Pan (L)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511; lainga.chan@yale.edu markus.muschen@yale.edu.
Department of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, 350001 Fujian, China.

Chao Hong (C)

Department of Laboratory Medicine, University of California, San Francisco, CA 94143; lainga.chan@yale.edu markus.muschen@yale.edu.

Lai N Chan (LN)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511; lainga.chan@yale.edu markus.muschen@yale.edu.

Gang Xiao (G)

Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA 91016.

Parmanand Malvi (P)

Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 32533.

Mark E Robinson (ME)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511.

Huimin Geng (H)

Department of Laboratory Medicine, University of California, San Francisco, CA 94143.

Srinivasa T Reddy (ST)

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.

Jaewoong Lee (J)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511.

Vishal Khairnar (V)

Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA 91016.

Kadriye Nehir Cosgun (KN)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511.

Liang Xu (L)

Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA 91016.

Kohei Kume (K)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511.

Teresa Sadras (T)

Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA 91016.

Shaoyuan Wang (S)

Department of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, 350001 Fujian, China.

Narendra Wajapeyee (N)

Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 32533.

Markus Müschen (M)

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511; lainga.chan@yale.edu markus.muschen@yale.edu.
Department of Immunobiology, Yale University, New Haven, CT 06511.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH